Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Caris Life Sciences Stock

Q: How to sell Caris Life Sciences stock?

If you hold private company shares of Caris Life Sciences - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Caris Life Sciences stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

carislifesciences.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $465MM

Operator of a biotechnology company specializing in cancer treatment agents. The company is a provider of molecular science focused on fulfilling the promise of precision medicine and facilitating a deeper understanding of cancer biology and other complex diseases through a suite of molecular profiling offerings assess DNA, RNA and proteins that reveal the molecular blueprint, enabling physicians and cancer patients to make more precise and personalized treatment decisions.

Buy or sell Caris Life Sciences stockLearn more about Caris Life Sciences IPO

OverviewFinancingsValuation

Enterprise Value

Access Caris Life Sciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Caris Life Sciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Caris Life Sciences investors also invested in these private companies

Coatue Management

Cerebras, Form Energy, Hugging Face, Scale AI, M1 Finance, Ramp, Relativity Space, Runway, Skild AI, Rippling

Fidelity Management & Research

Tenstorrent, Relativity Space, Epic Games, Nuro, Lightmatter, Element Biosciences, Astera Labs, Frore Systems, SiMa ai, Cleerly

T. Rowe Price

KoBold Metals, Databricks, Waymo, Redwood Materials, ADARx Pharmaceuticals, Sila Nanotechnologies, SandboxAQ, Tanium, Nuro, Stash

ClearBridge

DataStax, Caris Life Sciences

Neuberger Berman

Savage X Fenty, BillionToOne, Caris Life Sciences, Prosper, Gympass, Wayflyer, ProducePay, DoubleVerify, Anvilogic

Silver Lake

Waymo, Fanatics, Carbon, ThoughtSpot, Demandbase, Alchemy, Verily Life Sciences, Caris Life Sciences, Noom, Getir

Rock Springs Capital

Freenome, Zenas BioPharma, Caris Life Sciences, Delfi Diagnostics, Kindbody, FogPharma, Vedanta Biosciences, Hemab Therapeutics, Mineralys

Sixth Street Partners

ContentSquare, Caris Life Sciences, SnapLogic, Guesty

Millennium Management

Side, Caris Life Sciences, Starling Bank, Cardurion Pharma

OrbiMed

ADARx Pharmaceuticals, Carrot, BioAge, Insilico Medicine, Capstan Therapeutics, Caris Life Sciences, Delfi Diagnostics, Sionna Therapeutics, Scorpion Therapeutics, Iambic Therapeutics

J.H. Whitney Capital Partners

Caris Life Sciences

Team

Management Team

David Halbert

Co-Founder, Chairman and Chief Executive Officer

Ginger Appleberry JD

Chief Compliance Officer & Associate General Counsel

Brian Lamon Ph.D

Chief Business Officer & Head of BioPharma Business Development

Thomas Parker

Chief Financial Officer and Senior Vice President

Ronald Merlino

Senior Vice President & Chief Information Officer

Jim Abraham

Chief Data Officer & Senior Vice President

David Spetzler Ph.D

President & Chief Scientific Officer

Stephanie Thomas

Chief of Staff, Executive Vice President & Office of the CEO

Board Members

Peter Castleman

J.H. Whitney Capital Partners

Vijay Mohan

Sixth Street Specialty Lending

Caris Life Sciences stock FAQs

Can you buy Caris Life Sciences stock?

As Caris Life Sciences is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Caris Life Sciences, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Caris Life Sciences stock?

To invest in a private company like Caris Life Sciences through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Caris Life Sciences stock?

Yes, you may be able to sell your Caris Life Sciences stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Caris Life Sciences stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Caris Life Sciences stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Caris Life Sciences a public company?

No, Caris Life Sciences is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Caris Life Sciences’ stock price?

Caris Life Sciences is a privately held company and therefore does not have a public stock price. However, you may access Caris Life Sciences’ private market stock price with Forge Data.

What is Caris Life Sciences’ stock ticker symbol?

Caris Life Sciences does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

CISION 08/29/2022

Caris' Precision Oncology Alliance Welcomes the OU Health Stephenson Cancer Center

OU Health Stephenson Cancer Center joins Caris' extensive network of leading cancer institutions committed to utilizing clinical data to advance patient care and outcomes

Genomeweb 04/14/2022

In Brief This Week: Illumina, Caris Life Sciences, Fresenius Medical Care, More

News items for the week of April 11, 2022.

Genomeweb 10/29/2021

In Brief This Week: Ginkgo Bioworks, Caris Life Sciences, MDxHealth, and More

News items for the week of Oct. 25, 2021.

Genomeweb 10/14/2021

Caris Life Sciences, Ono Pharmaceutical Ink Cancer Drug Development Collaboration

The pharma firm will use Caris' comprehensive sequencing services, including its liquid biopsy assay, to advance development of targeted and immuno-oncology drugs.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.